Deucravacitinib: Non-interventional observational study of patients receiving treatment with commercially available deucravacitinib 6 mg once daily according to the Summary of Product Characteristics
Study summary
The purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practice in Germany over a 5-year period
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients with a physician-reported diagnosis of moderate-to-severe plaque psoriasis initiating deucravacitinib according to approved label in the European Union
* The decision upon treatment with deucravacitinib must have been made before enrollment and independently of this non-interventional observational study
* Patient is at least 18 years of age at the time of treatment decision
* Patient provided written informed consent to participate in the study
Exclusion Criteria:
* Any contraindications according to the approved deucravacitinib Summary of Product Characteristics
* Prior treatment with deucravacitinib
* Simultaneous participation in an interventional clinical trial for moderate-to-severe psoriasis
Primary outcome measure(s)
Proportion of patients achieving an absolute Psoriasis Area Severity Index (aPASI) score ≤ 3 at Week 24 or nearest visit — Approximately 24 weeks after treatment initiation (data to be collected at visit nearest to this timepoint)
Trial sites (2)
Facility
City
Region
Status
Dermatologische Spezial- und Schwerpunktpraxis Selters
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.